Dublin, Aug. 22, 2023 (GLOBE NEWSWIRE) -- The "Global Neurotrophic Keratitis Market (2023-2028) by Route of Administration, Distribution Channel, and Geography, Competitive Analysis, Impact of ...
As per DelveInsight analysis, the neurotrophic keratopathy market size in the 7MM was approximately USD 182 million in 2022. The total neurotrophic keratopathy prevalent cases in the 7MM comprised ...
Please provide your email address to receive an email when new articles are posted on . Welcome to another edition of CEDARS/ASPENS Debates. CEDARS/ASPENS is a society of cornea, cataract and ...
Refractory dry eye in patients with systemic comorbidities can be challenging to manage because the underlying condition or ...
The US Food and Drug Administration (FDA) has approved cenegermin (Oxervate, Dompé Farmaceutici S.p.A.), the first drug to treat neurotrophic keratitis. Neurotrophic keratitis is a rare degenerative ...
Please provide your email address to receive an email when new articles are posted on . Chang: Neurotrophic keratitis is a degenerative corneal disease, which means that the disease will worsen or at ...
MILAN and SAN BRUNO, Calif., Aug. 22, 2018 /PRNewswire/ -- Dompé today announced that the U.S. Food and Drug Administration (FDA) has approved Oxervate TM (cenegermin-bkbj ophthalmic solution), a ...
Dublin, April 29, 2021 (GLOBE NEWSWIRE) -- The "Neurotrophic Keratitis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and ...
The neurotrophic keratitis market reached a value of US$ 137.5 Million in 2023 and expected to reach US$ 248.0 Million by 2034, exhibiting a growth rate (CAGR) of 5.51% during 2024-2034. The ...
The dynamics of the neurotrophic keratopathy market are expected to increase in the forecast period. Compared to 2019, massive growth is expected in the 7MM neurotrophic keratopathy market. Along with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback